Revelstoke Capital Partners Seizes Opportunity with AOM Infusion Investment

Revelstoke Capital Partners Makes Strategic Move with AOM Infusion

In a significant step for healthcare investments, Revelstoke Capital Partners, a private equity firm with a strong focus on the industry, has recently completed the recapitalization of AOM Infusion. This partnership marks their ninth investment from Revelstoke Capital Partners Fund III, reinforcing their commitment to enhancing patient care in specialty infusion therapy.

Expanding Access to Specialty Infusion Therapies

AOM Infusion is dedicated to providing patients with a variety of chronic therapy options, including Intravenous Immunoglobulin (IVIG) and other biologics. With a mission to serve over 80 chronic conditions, AOM prides itself on administering these therapies through skilled infusion nurses. Additionally, the company offers crucial support services such as pharmacy management, referral assistance, insurance verification, and patient education, ensuring that the patients receive comprehensive care.

Anthony Hayes, a partner at Revelstoke, expressed admiration for AOM’s operational model and growth trajectory. He stated, “Revelstoke strives to partner with strong management teams to build industry-leading companies.” He further noted that the partnership intends to support AOM’s leadership as they navigate the next phase of their evolution in infusion therapy.

A Vision for Patient-Centric Growth

Keyur Mehta, CEO of AOM Infusion, shared his enthusiasm for the partnership, articulating the company's commitment to growth that improves patient care. He highlighted their objective to extend their therapeutic reach, deepen clinical expertise, and ensure patients achieve the highest quality of infusion therapy in comfortable settings. Mehta's vision aligns with Revelstoke's investment strategy, as the firm recognizes the changing landscape of care and the increasing relevance of specialty infusion therapies.

Eric Hale, Vice President at Revelstoke, indicated the strategic importance of the specialty infusion sector, commenting on the ongoing shift in care settings and the expanding pipeline of infusible drugs. He specified that Revelstoke has monitored AOM’s progress over recent years and believes the company is aptly equipped for future success in this specialized domain.

Financial Backing and Advisors

The transaction was completed with the guidance of financial advisors including Guggenheim Securities and Houlihan Lokey for Revelstoke, while Jefferies and Moelis advised AOM Infusion. McGuireWoods LLP provided legal counsel throughout the negotiation process.

About AOM Infusion and Revelstoke Capital Partners

Founded in 1994, AOM Infusion has established itself as a leader in providing IVIG, biologics, and other therapies across the United States, boasting pharmacy licenses in all 50 states. AOM is driven by a mission to deliver exceptional patient experiences that enhance overall health through personalized care.

In contrast, Revelstoke Capital Partners emphasizes building companies in healthcare services, technology, and wellness sectors. With approximately $4.8 billion in assets under management and a significant history of 195 acquisitions since its inception in 2013, Revelstoke aims to partner with entrepreneurs to execute strategic growth initiatives.

As both entities embark on this new journey together, they share a commitment to elevating the standards of care in the healthcare industry, ultimately paving the way for improved outcomes for patients with chronic conditions.